Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sunitinib malate.

Hassane Izzedine1, Irina Buhaescu, Olivier Rixe

  • 1Department of Nephrology, Pitie-Salpetriere Hospital 83, Blvd de l'Hôpital, 75013 Paris, France. hassan.izzedine@psl.ap-hop-paris.fr

Cancer Chemotherapy and Pharmacology
|December 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Microplastics and Nanoplastics on the Kidneys.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

QT-prolonging medications: prevalence of use and associated risks in CKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate.

Fundamental & clinical pharmacology·2025
Same author

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.

Cancer·2025
Same author

Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.

The oncologist·2025
Same author

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Sunitinib, a multi-targeted tyrosine kinase inhibitor, shows anti-tumor and anti-angiogenic effects. It is approved for advanced renal cell carcinoma and gastrointestinal stromal tumors resistant to imatinib.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) like VEGFR, PDGFR, KIT, and FLT3 play key roles in tumor angiogenesis, growth, and metastasis.
  • Understanding RTK roles is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To review pharmacologic and clinical data of sunitinib, a novel multi-targeted tyrosine kinase inhibitor.
  • To highlight sunitinib's efficacy in oncology.

Main Methods:

  • Review of recent pharmacologic and clinical data.
  • Focus on sunitinib's binding affinity for VEGFR and PDGFR.

Main Results:

  • Sunitinib exhibits anti-tumor and anti-angiogenic activities.
  • Sunitinib received FDA approval for advanced renal cell carcinoma (adRCC) and gastrointestinal stromal tumors (GIST) in imatinib-resistant patients.

Related Experiment Videos

Conclusions:

  • Sunitinib is a promising oral, multi-targeted tyrosine kinase inhibitor for specific cancer indications.
  • The drug offers a new therapeutic option for patients with advanced RCC and GIST.